Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
The biologics development and manufacturing facility taken over from Vaccine Manufacturing and Innovation Centre UK Ltd. is locaterd n to the south of Oxford at the world-renowned Harwell Science and Innovation Campus, a leading site in the UK for science and technology breakthroughs and home to more than 40 life science companies.
Catalent plans to invest up to $160m to complete the building of the facility and equip it with state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced modalities. The new facility will employ more than 400 people and support public and private organisations to develop and manufacture biotherapeutics.
The acquisition complements recent investments into Catalent’s biotherapeutics network. The business recently completed a $30m project for biopharmaceutical development and drug product manufacturing at its early-stage and small-scale facility in France. The European Biotherapeutics network also includes late-stage/commercial biologics manufacturing in Belgium and Italy.